This was revealed during ASCO, which was held in Chicago.
The Center Georges François Leclerc introduced us to the latest medical advances presented at the ASCO (American Society of Clinicat Cncology) that took place in Chicago in the last few days. And the presentation of the results of the Destiny – Breast 04 study was greeted with a standing ovation. This study showed the effectiveness of an antibody against the HER2 cell in patients with breast cancer. The antibody will act like a Trojan horse to attack cancer cells directly by delivering a dose of chemotherapy.
The press conference took place in the presence of Dr. Jean David Fumet, Dr. Alice Hervieu, Dr. Leïla Bengrine-Lefevre, Professor Charles Coutant and Professor Sylvain Ladoire.
© Photos Manon Bollery
Professor Sylvain Ladoire
“There was a real revolution this year. We are in a change of direction. »
“There was a therapeutic study based on antibodies”
“We’ve talked a lot about immunotherapies over the last few years, but this is a lot more than that.
The principle is to take an antibody that recognizes something on the surface of tumor cells
This antibody attaches itself to a protein, and these antibodies transfer the chemotherapy to the cells. »
“This new treatment technique is a bit like ‘The Trojan horse of chemotherapy’
“Breast cancer is the flag of this Trojan horse, but it will develop in all cancers”
“At ASCO, the real revolution comes from a Destiny – Breast 04 study that targeted patients with metastatic breast cancer. »
“The target of the antibody is HER2. »
“This is the greatest advance we’ve seen in the history of breast cancer. It halves the risk of progression and reduces the risk of death by 37%. »
“There were real standing ovations. This is very rare, the room got up. This is proof that it is a domain change. It validates the concept that ADCs will revolutionize the field of cancer treatment. »
“The real revolution is that it is not necessary to have high HER2 expression. This works not only for tumors that express high but also low levels of HER2. »
“It’s a treatment that will be available for more than half of breast cancers. It is much more effective than traditional chemotherapy. However, it is not without its toxicity (hair loss, nausea…), the side effects are similar to those of traditional chemotherapy. »
“This is not a new drug, but a new family of drugs. »
“The CGFL has opened studies with each of these ADCs. »
“We hope to be able to cure more patients with this new family of drugs. 1 in 2 patients can benefit from this molecule. This is one of the main goals of the CGFL. »
“Last year, every third patient benefited from an innovation. »
“This molecule is already being reimbursed in a niche of certain breast cancers
This allows if the authorities poke their nose in it may be accessible (refunded) for the coming months (until January). »
“This is the big scoop of breast cancer and it will cause us to have the same outcome in the face of one tumor anywhere in the field. »
“A big Canadian study happened: stopping radiation therapy after surgery. Basically, you receive less toxic treatments without compromising your chances of survival.
Many tumors are detected very early in mammography screening.
The study showed that patients without radiotherapy have an acceptable risk of recurrence (2%). On the other hand, if you stop irradiating patients, you no longer produce side effects. »
“We must achieve a de-escalation of the use of radiotherapy”
#MEDICINE #CGFL #presented #Trojan #Horse #chemotherapy